|By PR Newswire||
|August 25, 2014 11:43 AM EDT||
MARLBOROUGH, Mass., Aug. 25, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today released additional research and comments on Ligand Pharmaceuticals (NASDAQ: LGND) amidst the company's unusual and complex debt arrangement under which the firm has assumed $245 million in debt principally so that large institutional shareholders can offload shares of the troubled company in private transactions at undisclosed prices. In what is likely the first in a series of large institutional share sales of Ligand, the company's largest shareholder, BVF, Inc., revealed to the U.S. Securities and Exchange Commission (SEC) this week that it has sold 484,524 shares of the company's stock.
"Ligand Pharmaceuticals is an insolvent company facing severe competitive threats to its key royalty programs that has now absorbed an extraordinary amount of costly debt apparently to allow their largest shareholders to liquidate their holdings as 'going concern risk' at the company grows," Lemelson Capital Management Chief Investment Officer Emmanuel Lemelson said today. "This transaction reaffirms our prior research thesis that Ligand has justifiably lost favor with its largest investors and has dramatically increased the likelihood of the company eventually being forced to seek protection from creditors," he added.
The report on Ligand can be found here.
Lemelson Capital Management first announced its short position in Ligand Pharmaceuticals on June 16, 2014. The stock has undergone a significant 26 percent correction since. "We reiterate our position that the intrinsic value for Ligand is zero and see these large institutional sales as an indication that our concerns are increasingly broadly held," Lemelson said.
Disclosure: Lemelson Capital is currently short shares of LGND for its clients.
About Lemelson Capital Management:
Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds. For more information, see: http://www.lemelsoncapital.com.
Chief Investment Officer
Lemelson Capital Management, LLC
SOURCE Lemelson Capital Management, LLC
Nov. 27, 2015 01:00 PM EST Reads: 160
Nov. 27, 2015 01:00 PM EST Reads: 138
Nov. 27, 2015 12:00 PM EST Reads: 460
Nov. 27, 2015 12:00 PM EST Reads: 538
Nov. 27, 2015 11:45 AM EST Reads: 535
Nov. 27, 2015 11:00 AM EST Reads: 309
Nov. 27, 2015 10:45 AM EST Reads: 396
Nov. 27, 2015 10:45 AM EST Reads: 383
Nov. 27, 2015 10:00 AM EST Reads: 305
Nov. 27, 2015 10:00 AM EST Reads: 490
Nov. 27, 2015 09:45 AM EST Reads: 216
Nov. 27, 2015 09:15 AM EST Reads: 288
Nov. 27, 2015 08:00 AM EST Reads: 376
Nov. 27, 2015 07:45 AM EST Reads: 422
Nov. 27, 2015 07:30 AM EST Reads: 317